Search PubMed⌕ Search
Home/Archive/PubMed

PubMed · 14628078

Donor commitment and patient needs.

R Bakken·A-M van Walraven·T Egeland·Ethics Working Group of the World Marrow Donor Association
View original source ↗Export metadata ↓

Abstract

The article discusses views and recommendations of the World Marrow Donor Association concerning ethical issues related to the donation of hematopoietic stem cell products with respect to recruitment, evaluation, workup, and follow-up of unrelated donors. Particular emphasis is placed upon commitment of individual donors, in particular, with respect to the needs of patients to find HLA-matched donors, who may be asked to donate stem cell and other cell products more than once for given patients.

Explore related subjects

Hematopoietic Stem Cell TransplantationHumansInformed ConsentRegistriesTissue DonorsHealth Care and Public HealthGuidelineJournal ArticlePractice Guideline

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

R Bakken, A-M van Walraven, T Egeland, Ethics Working Group of the World Marrow Donor Association. 2004. Donor commitment and patient needs.. https://doi.org/10.1038/sj.bmt.1704323

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2006

Optimization of allogeneic transplant conditioning: not the time for dogma.

Numerous reduced-intensity conditioning regimens for allogeneic hematopoietic cell transplantation are currently being explored, primarily in older patients and in individuals with comorbid conditions who are not eligible for conventional myeloablative conditioning regimens. There is agreement that these approaches have reduced early transplant-related (non-relapse) toxicity and mortality. It is unclear, however, whether these strategies improve long-term survival. Furthermore, as most trials with reduced-intensity regimens have enrolled older patients and patients with comorbid conditions, it is not appropriate to compare the results of these trials to those obtained with more conventional approaches. It remains to be determined whether younger patients, and patients without comorbid conditions, will derive significant long-term benefits from reduced-intensity regimens when compared to conventional strategies. It may be that the different approaches are complementary and in the end will preferentially serve specific patient populations based on age, comorbid conditions and malignancy type. To determine the role of reduced-intensity approaches, controlled prospective trials are needed, with enrolled patients being stratified according to comorbid conditions, disease characteristics, pre-transplant therapy and source of stem cells, at a minimum.

Hematopoietic Stem Cell Transplantation↗